Angiotech Pharmaceuticals announced a licensing deal with Baxter for COSEAL, Angiotech’s surgical sealant; Baxter pays $25M [ PR Newswire ] Shire Pharmaceuticals and GSK will team up to promote Vyvanse in the US. [ WSJ ] Wyeth submits marketing application to FDA for its 13-valent vaccine for the prevention of pneumococcal disease in infants and toddlers. [ Reuters ] Takeda Pharmaceuticals moving its R&D facilities to Chicago; creates jobs. [ Los Angeles Times ] Astra’s R Shares of GlaxoSmithKline PLC and Shire Ltd. advanced Tuesday after the drug developers signed a deal to co-promote the attention deficit hyperactivity disorder drug Vyvanse in the United States. The drug, made by Ireland-based Shire (nasdaq: SHPGY - news - people ), was first approved in 2007 for children between 6 and 12 years old and then again in 2008 for adults. The three-year deal will help expand the company's marketing reach while giving U.K.-based GlaxoSmithKline (nyse: GSK - news * U.S. co-promotion will double Vyvanse sales effort * Three-year profit sharing deal targets adults with ADHD * Shire shares jump 7.2 percent (Adds analyst comment, shares) LONDON, March 31 (Reuters) - Shire (SHP.L) has struck a dealwith GlaxoSmithKline (GSK.L), the world's second largest drugsgroup, to co-promote its hyperactivity medicine Vyvanse in theUnited States , sending its shares sharply higher. Shire, Glaxo Enter Vyvanse Co-Promotion Agreement US called ill equipped f RESEARCH TRIANGLE PARK, N.C., March 31 /PRNewswire-FirstCall/ -- GlaxoSmithKline plc (NYSE: GSK) has entered into a co-promotion agreement with Shire plc (LSE: SHP, Nasdaq: SHPGY) for Vyvanse(R), to help improve the recognition and treatment of adult